摘要
目的探讨他汀类药物在COPD急性加重期应用的临床意义。方法选取60例入住病房的AECOPD患者,随机分为实验组(使用瑞舒伐他汀)30例,对照组30例,均给予常规氧疗、抗感染、解痉平喘、化痰等治疗,实验组同时给予瑞舒伐他汀5mg,口服,每晚一次,连续治疗10天。治疗前后分别检查患者血浆中的白介素-6(IL-6)、C-反应蛋白(C-RP)、肿瘤坏死因子-α(TNF-α)水平的变化。结果治疗结束后,两组患者血浆中IL-6、TNF-α、C-RP改善程度均有统计学意义(P<0.01);实验组较对照组中IL-6、TNF-α、C-RP改善程度有统计学意义(P<0.05)。结论他汀类药物在治疗慢性阻塞性肺疾病急性加重期患者中,能减低患者体内的IL-6、TNF-α、C-RP水平,从而缓解患者体内急性炎症反应和免疫反应,减轻肺组织的炎症损伤。
Objective To investigate the clinical significance of statins in the treatment of patients with chronic obstructive pul- monary disease （COPD） at acute exacerbation. Methods 60 patients with AECOPD were randomly and evenly divided into two groups. All patients were given conventional oxygen therapy, anti-infective, antispasmodic asthma, and phlegm elimination treatment, and the ex- periment group was additionally treated with 5 mg of rosuvastatin orally once a day for 10 consecutive days. The levels of interleukin-6 （ 1L- 6） , C-reactive protein （CRP） , and tumor necrosis factor-a （TNF-ct） were measured before and after the treatment. Results After the treatment, the levels of IL-6, TNF-a, and CRP were obviously improved （P 〈0. 01 ）, and the improvement was more pronounced in the experiment group than in the control group （ P 〈 0.05 ）. Conclusion Statins can reduce the levels of IL-6, TNF-a and CRP significantly so as to ease lhe patients＇acute inflammation reaction and immune response in the treatment of patients with AECOPD.
出处
《临床肺科杂志》
2013年第10期1770-1772,共3页
Journal of Clinical Pulmonary Medicine
